54.174.225.82
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
FDA Alerts
Hematology
Trending Topics

FDA grants priority review for pembrolizumab plus chemotherapy for esophagus cancer

Posted on December 17, 2020

The U.S. Food and Drug Administration has granted priority review for a new supplemental biologics license application for pembrolizumab (Keytruda; Merck) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of patients with locally advanced unresectable or metastatic carcinoma of the esophagus and gastroesophageal junction (GEJ), according to a press release.

The application was based on data from the Phase 3 KEYNOTE-590 trial which found pembrolizumab plus chemotherapy significantly improved overall survival and progression-free survival compared with chemotherapy in patients regardless of PD-L1 expression status and tumor histology.

“Patients with newly diagnosed esophageal and GEJ cancer face an aggressive disease with a poor prognosis, despite the currently available treatment options,” said Dr Vicki Goodman, vice president, clinical research, Merck Research Laboratories, in a press release. “We look forward to working with the FDA to bring a new option to patients in the first-line setting.”

Read the full press release here.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-